Health News Roundup: Bayer ordered to pay $2.25 billion in latest Roundup trial; China's MGI Tech, GemPharmatech defend themselves after US bill proposed

A jury in the Philadelphia Court of Common Pleas found that John McKivision's non-Hodgkins lymphoma was the result of using Roundup for yard work at his house for a period of several years. The verdict includes $250 million in compensatory damages and $2 billion in punitive damages.

Following is a summary of current health news briefs.

China's MGI Tech, GemPharmatech defend themselves after US bill proposed

China's MGI Tech said on Sunday as an upstream equipment provider in the gene sequencing industry, its business does not involve data collection, after a proposed U.S. Biosecure Act included its name in the bill. "The data generated by customers based on our sequencing platform are collected, stored, processed and controlled by the customers themselves," MGI Tech said in a filing to the Shanghai stock exchange.

Bayer ordered to pay $2.25 billion in latest Roundup trial

Bayer was ordered on Friday to pay $2.25 billion to a Pennsylvania man who said he developed cancer from exposure to the company's Roundup weedkiller, the man's attorneys said. A jury in the Philadelphia Court of Common Pleas found that John McKivision's non-Hodgkins lymphoma was the result of using Roundup for yard work at his house for a period of several years. The verdict includes $250 million in compensatory damages and $2 billion in punitive damages.